Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ironwood Pharmaceuticals, Inc.    IRWD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about IRONWOOD PHARMACEUTICALS,
01/17 Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
01/04 IRONWOOD PHARMACEUTICALS : to Present at J.P. Morgan Healthcare Conference
01/02 IRONWOOD PHARMACEUTICALS : to Present at J.P. Morgan Healthcare Conference
2017 IRONWOOD PHARMACEUTICALS : Initiates Phase II Clinical Trial of sGC Stimulator I..
2017 IRONWOOD PHARMACEUTICALS : Reports Top-line Phase IIa Data for IW-1973 Demonstra..
2017 IRONWOOD PHARMACEUTICALS : Reports Top-line Phase IIa Data for IW-1973 Demonstra..
2017 IRONWOOD PHARMACEUTICALS : Strengthens Executive Leadership Team
2017 IRONWOOD PHARMACEUTICALS : to Present at Credit Suisse 26th Annual Healthcare Co..
2017 IRONWOOD PHARMACEUTICALS : Provides Third Quarter 2017 Investor Update
2017 IRONWOOD PHARMACEUTICALS : reports 3Q loss
2017 IRONWOOD PHARMACEUTICALS : Provides Third Quarter 2017 Investor Update
2017 IRONWOOD PHARMACEUTICALS : to Present at Credit Suisse 26th Annual Healthcare Co..
2017 IRONWOOD PHARMACEUTICALS : Highlights Breadth of Gout Research to be Presented a..
2017 IRONWOOD PHARMACEUTICALS : Highlights Breadth of Gout Research to be Presented a..
2017 IRONWOOD PHARMACEUTICALS : to Host Third Quarter 2017 Investor Update Call
More most relevant news
All news about IRONWOOD PHARMACEUTICALS,
01/17 Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
01/11 IRONWOOD PHARMACEUTICALS : to Present at J.P. Morgan Healthcare Conference
01/08 IRONWOOD PHARMACEUTICALS INC : Results of Operations and Financial Condition (fo..
01/04 IRONWOOD PHARMACEUTICALS : to Present at J.P. Morgan Healthcare Conference
01/02 IRONWOOD PHARMACEUTICALS : to Present at J.P. Morgan Healthcare Conference
2017 IRONWOOD PHARMACEUTICALS : Initiates Phase II Clinical Trial of sGC Stimulator I..
2017 IRONWOOD PHARMACEUTICALS : Price to Cash Flow Under Review
2017 IRONWOOD PHARMACEUTICALS : Initiates Phase II Clinical Trial of sGC Stimulator I..
2017 IRONWOOD PHARMACEUTICALS : Reports Top-line Phase IIa Data for IW-1973 Demonstra..
2017 IRONWOOD PHARMACEUTICALS : Strengthens Executive Leadership Team
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a Drug Firms Bet Billions on Biotech -- WSJ
01/22 Stocks hit record as senators reach deal to end shutdown
01/22 Big Drugmakers Pay Big Prices for Promising Biotechs
01/22 Dealmaking drives European stocks as equity melt-up continues
01/22 Biotech M&A takes off as Sanofi and Celgene spend $20 billion
01/22 CELGENE : to Buy Juno Therapeutics for $9 Billion -- 2nd Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/16 Ironwood and Allergan settle Linzess patent infringement suit with Sun Pharma
01/09 Ironwood Pharmaceuticals (IRWD) Presents At 36th Annual J.P. Morgan Healthcar..
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
01/08 Synergy Pharmaceuticals' Trulance Enters Its Sophomore Year
01/05 BofA/Merrill Lynch bullish on biopharma in 2018
01/05 More premarket analyst action - healthcare
Latest Tweets
01/21Zacks Investment Research Upgrades Ironwood Pharmaceuticals $IRWD to Hold  
01/16Ironwood and Allergan settle Linzess patent infringement suit with Sun Pharma.. 
01/16Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® .. 
01/16$IRWD $AGN Announce Settlement With Sun Pharma Resolving LINZESS Patent Litig..
1
01/16Our team reviews key themes for 2018 and previews 4Q earnings, including $AG..
1
More tweets
Qtime:49
Financials ($)
Sales 2017 290 M
EBIT 2017 -116 M
Net income 2017 -127 M
Debt 2017 301 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 9,29x
EV / Sales 2018 7,24x
Capitalization 2 395 M
Chart IRONWOOD PHARMACEUTICALS,
Duration : Period :
Ironwood Pharmaceuticals,  Technical Analysis Chart | IRWD | US46333X1081 | 4-Traders
Technical analysis trends IRONWOOD PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 16,3 $
Spread / Average Target 1,6%
EPS Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Terrance G. McGuire Chairman
William I. Huyett Chief Operating Officer
Gina R. Consylman CFO, CAO, Controller & VP-Finance
Mark G. Currie Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
IRONWOOD PHARMACEUTICALS, INC.2.60%2 395
CELLTRION, INC.--.--%32 824
IQVIA HOLDINGS INC5.21%21 389
LONZA GROUP2.62%20 968
INCYTE CORPORATION-1.64%19 854
ALNYLAM PHARMACEUTICALS, INC.-1.75%12 881